Author:
Garimella Tushar,You Xiaoli,Wang Reena,Huang Shu-Pang,Kandoussi Hamza,Bifano Marc,Bertz Richard,Eley Timothy
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference39 articles.
1. World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva, Switzerland. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ . Accessed April 15, 2015.
2. Kiser JJ, Burton JR Jr, Everson GT. Drug–drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596–606.
3. McPhee F, Suzuki Y, Toyota J, et al. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv Ther. 2015;32:637–49.
4. Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA. 2015;313:1728–35.
5. Muir AJ, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313:1736–44.
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献